Primecap Management Co. CA Has $1.21 Million Stock Position in OraSure Technologies, Inc. (NASDAQ:OSUR)

Primecap Management Co. CA lessened its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 52.5% in the fourth quarter, Holdings Channel reports. The firm owned 336,300 shares of the medical instruments supplier’s stock after selling 371,850 shares during the quarter. Primecap Management Co. CA’s holdings in OraSure Technologies were worth $1,214,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Raymond James Financial Inc. bought a new position in OraSure Technologies in the 4th quarter valued at about $37,000. Atom Investors LP acquired a new stake in shares of OraSure Technologies during the 3rd quarter worth approximately $49,000. US Bancorp DE increased its stake in OraSure Technologies by 310.4% in the fourth quarter. US Bancorp DE now owns 19,433 shares of the medical instruments supplier’s stock valued at $70,000 after acquiring an additional 14,698 shares during the last quarter. Aigen Investment Management LP acquired a new position in OraSure Technologies during the fourth quarter valued at approximately $76,000. Finally, Intech Investment Management LLC bought a new stake in OraSure Technologies during the third quarter worth $84,000. Institutional investors own 93.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th.

OraSure Technologies Trading Up 1.4 %

OSUR stock opened at $3.51 on Thursday. The firm has a 50-day moving average price of $3.72 and a 200-day moving average price of $3.92. OraSure Technologies, Inc. has a 12 month low of $2.69 and a 12 month high of $6.69. The stock has a market capitalization of $262.55 million, a P/E ratio of 23.40 and a beta of -0.02.

Insider Buying and Selling

In related news, Director John P. Kenny purchased 47,659 shares of the stock in a transaction dated Thursday, February 27th. The stock was bought at an average cost of $3.17 per share, for a total transaction of $151,079.03. Following the completion of the acquisition, the director now owns 70,915 shares of the company’s stock, valued at approximately $224,800.55. This represents a 204.93 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kenneth J. Mcgrath purchased 64,000 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was purchased at an average price of $3.15 per share, with a total value of $201,600.00. Following the completion of the purchase, the chief financial officer now directly owns 371,013 shares in the company, valued at $1,168,690.95. The trade was a 20.85 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 190,284 shares of company stock worth $600,348 in the last three months. 3.40% of the stock is owned by corporate insiders.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.